Objective: Glioma is one of the leading causes of death worldwide with high incidence, recurrence, and mortality. Interleukin-10 (IL-10) is a cytokine with dual function in many types of tumors. Although IL-10 is overexpressed and promotes tumor progression in human primary brain tumor, the mechanisms are largely unknown.
INTRODUCTION
Glioma is the most common tumor arising from the central nervous system with an incidence of 22/100,000 population, [1] accounting for 75% of malignant primary brain tumors in adults. [2] It initiates from glial or precursor cells, and the 5-year survival rates are around 10%. [3] Currently, the therapeutic strategies for glioma are surgical resection, combined with radiotherapy (RT), chemotherapy, and/or targeted therapy according to the molecular features of the tumor for patients with newly diagnosed with glioma. [4] However, glioma remains incurable and its poor prognosis contributes to high rates of recurrence. Thus, it is essential to develop new strategies to inhibit glioma progression.
Interleukin-10 (IL-10) was first considered as a T helper 2 cytokine, which modulates the growth and differentiation of innate immune cells, endothelial cells, and keratinocytes and suppresses the activation and functions of T-cells. [5] Numerous kinds of cells can produce IL-10, such as Tregs, B-cells, macrophages, mast cells, dendritic cells, and epithelial cells in mice and human. [6, 7] IL-10 was regarded as a suppressive factor that impaired the proliferation, cytokine production, and migration of effector T-cells; [8] elevated level of IL-10 inhibited cytolytic activity in transplanted tumors. [9, 10] In the context of tumor, IL-10 is a double-edged sword. IL-10 administration suppressed tumor growth and led to tumor rejection in a variety of tumors, such as melanoma, sarcomas, and colorectal cancer. [11] [12] [13] [14] Conversely, IL-10 can also promote the development of lung cancer, esophageal squamous cell carcinoma, melanoma, and cervical carcinoma. [15] [16] [17] [18] In human brain tumor, IL-10 is overexpressed in human glioma, and its overexpression increases glioma cell proliferation and motility and promotes tumorigenesis. [19] [20] [21] [22] Access this article online Website: www.cancerjournal.net DOI: 10.4103/jcrt.JCRT_284_19
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KPNA2 is a member of karyopherin α family which belongs to a family of nuclear transport proteins. [23] KPNA2 is composed of an N-terminal hydrophilic importin β -bingding domain, a central hydrophobic region, and a short acidic C-terminus and functions through regulating the subcellular translocation of cancer-associated cargo proteins. [24, 25] It was reported that KPNA2 was overexpressed in a variety of types of cancer and promoted cell growth and survival, such as breast cancer, cervical cancer, colorectal cancer, and esophageal squamous cell carcinoma. [26] [27] [28] [29] [30] In human brain tumor, KPAN2 is overexpressed in meningiomas and infiltrative astrocytomas and correlates significantly with the histological grade and proliferative activity. [31, 32] In human glioblastoma, Lu et al. reported that MIR517C inhibited the epithelial-to-mesenchymal (-like) transition phenotype through KPNA2-dependent disruption of TP53 nuclear translocation, indicating that KPNA2 is correlated with glioblastoma development. [33] Therefore, whether IL-10-mediated inhibition of glioma cell growth and motility is dependent on KPNA2 remains unclear.
In this study, we first evaluated the effect of IL-10 on glioma cell growth and invasion. Then, the expression of KPNA2 was quantified by quantitative polymerase chain reaction (q-PCR) and knocked down using small interfering RNA (siRNA) to demonstrate the role of KPNA2 in glioma cell growth and invasion. This study will be of important significance and provides a potential target for treatment of patients with glioma.
MATERIALS AND METHODS
Cell line and cell culture Glioma cell line U87 was purchased from the American Type Culture Collection (ATCC, VA, USA) and cultured in RPMI-1640 (GIBCO, NY, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, UT, USA), 100 U/ml penicillin G, and 100 μg/ml streptomycin (Sigma-Aldrich, Shanghai, China) at 37°C in a 5% CO 2 incubator. In all experiments, U87 cells were trypsinized at 80% confluency for further experiments.
Cell proliferation assay
The CCK-8 assay was used to determine cell proliferation ability. In brief, cells were seeded at a density of 1 × 10 3 cells/well in 96-well plates and incubated overnight at 37°C. IL-10 was then added into the culture medium. At the indicated time points (1, 2, 3, and 4 days), 10 μl of CCK-8 solution was added into the culture medium, and the cells were incubated for an additional 1.5 h at 37°C. Then, the absorbance of each well was measured at 450 nm using a microplate reader (Elx800, BioTek, VT, USA). All experiments were performed in quintuplicate.
Cell invasion assay
Cell invasion was performed with a Transwell Chamber (3422, Corning, NY, USA) according to the manufacturer's instruction. In brief, 100 μl diluted matrigel was put into the upper chamber of the 24-well invasion chamber and incubated at 37°C in a 5% CO 2 atmosphere for 4-6 h to hydrate the matrigel. Then, 500 μl serum-free medium was added into the lower chambers for 30 min. Cells were resuspended in 100 μl serum-free media at a density of 10 6 cells/ml, and cell suspension was added into the upper chamber and 500μl completed medium was added into the lower chambers. After incubation overnight, cells on the upper surface of the filter membrane were scraped with cotton swabs, and those cells on the lower surface of the chamber were fixed with polyoxymethylene for 30 min and stained with 0.1% crystal violet solution for 20 min. Five visual fields were randomly selected and photographed under a light microscope at ×100 (Micropublisher 3.3RTV, Olympus, Tokyo, Japan), and the invaded cells were counted.
RNA extraction and quantitative real-time polymerase chain reaction Total RNA from U87 cells was extracted and purified using RNA extraction kit according to the manufacturer's protocol. Reserve transcription was performed to generate complementary DNA according to the manufacturer's protocol. The messenger RNA (mRNA) level of KPNA2 was measured by q-PCR using SYBR Premix Ex Tap. The primers were used as follows:
β-actin was used as internal control. The relative mRNA expression of these genes was calculated using the 2 −ΔΔCt method. [34] siRNA transfection The siRNAs were purchased from RiboBio Company (Guangzhou, China), and the sequence of siRNA for KPNA2 is as follows:
U87 cells were seeded in 6-well plates and cultured overnight. Next day, cells were transfected with the three siRNAs for KPNA2 at optimal concentration. Forty-eight hours later, cells were used for further experiments.
Statistical analysis
The Student's t-test was used to quantify the significant differences. GraphPad Prism 5 software (Graphpad, software, Inc, LaJolla, CA, USA) was used for statistical analysis. Data are presented as the mean ± standard deviation, and P < 0.05 was considered statistically significant.
RESULTS

Interleukin-10 promotes the proliferation of glioma cells
Cancer progression is a complex process involving cell growth, migration, invasion, colony formation, and metastasis.
examined the knockdown efficiency of KPNA2. As shown in Figure 4a , the expression of KPNA2 was significantly inhibited in U87 cells [ Figure 4a ] (P = 0.00852). We found that knockdown of KPNA2 significantly inhibited the cell growth of U87 cells at day 3 and day 4 compared with NC cells [ Figure 4b ] (P = 0.015472 and P = 0.0285163). Taken together, these data demonstrated that KPNA2 affected the glioma cell growth.
Knockdown of KPNA2 suppressed the invasion of glioma cells
We also assessed the effect of KPNA2 on cell invasion of U87 cells. The results showed that knockdown of KPNA2 significantly decreased the cell invasion of U87 cells [ Figure 5 ] (P = 0.033081433). Thus, we confirmed that KPNA2 contributes to the invasion of glioma cells. Taken together, we found that IL-10 promoted glioma cell progression via upregulation of KPNA2.
DISCUSSION
In this study, we report that IL-10 promotes cell growth and invasion in glioma cells. We found that IL-10 increased the expression of KPNA2, and knockdown of KPNA2 significantly inhibited the glioma cell growth and invasion, indicating that IL-10 promotes glioma cell growth and invasion via upregulation of KPNA2.
The survival rate in high-grade glioma patients receiving a combined regimen of RT and temozolomide after tumor resection was increased. However, cognitive deficits and depression after the treatments challenge the treatments. [35] Immunotherapy for cancer is a new and promising treatment method besides operation, RT, and chemotherapy. Moreover, it has been applied to treat malignancies, such as lung cancer, melanoma, renal carcinoma, and hematological malignancy. [36] IL-10 is a cytokine which plays a dual function in many types
To explore whether IL-10 affected glioma progression, we first detected the role of IL-10 in glioma cell growth. We cocultured glioma cell line U87 with different dosages of IL-10. After 24 h, CCK-8 assay was performed. We found that IL-10 promoted the cell growth of U87 in a dose-dependent manner [ Figure 1a ]. As shown in Figure 1a , IL-10 at the concentration of 50 ng/ml enhanced the proliferation of U87 cells much significantly than others [ Figure 1a ] (P = 0.02443235). Therefore, we used IL-10 at 50 ng/ml for further experiments. We also found that IL-10 significantly promoted the cell growth of U87 cells at day 4 compared with negative control (NC) cells [ Figure 1b ] (P = 0.024350635). Thus, these data demonstrated that IL-10 promotes the proliferation of glioma cells.
Interleukin-10 enhances the invasion of glioma cells
Next, we assessed the role of IL-10 in glioma cell invasion by cell invasion assay. As compared with NC cells, IL-10 treatment remarkably increases the number of invasion cells [ Figure 2a and b] (P = 0.049071933). These results demonstrated that IL-10 treatment enhanced the invasion of human glioma cells.
Interleukin-10 increases the expression of KPNA2 in glioma cells
We further explored the mechanisms by which IL-10 promoted the glioma cell proliferation and invasion. Many studies have shown that KPNA2 played a role in cell growth and invasion of many cancer cells, including human brain tumor. [26, 27, 29, 31, 32] Therefore, we examined the expression of KPNA2 in IL-10-treated U87 cells. We found that IL-10 significantly increased KPNA2 mRNA levels in U87 cells compared with untreated control cells [ Figure 3 ] (P = 0.02405).
Knockdown of KPNA2 inhibits the proliferation of glioma cells
To investigate the role of KPNA2 in glioma cell growth, we used siRNA to specifically silence KPNA2 in U87 cells. We first Figure 1 : Interleukin-10 enhances glioma cell proliferation. (a) U87 cells were cultured and treated with different concentrations (5 ng/ml, 10 ng/ml, 20 ng/ml, 25 ng/ml, 50 ng/ml, and 75 ng/ml) of interleukin-10 for 24 h, and then, CCK-8 assay was performed. The results were presented as mean ± standard deviation. *P < 0.05, **P < 0.01. (b) U87 cells were treated with or without interleukin-10 (50 ng/ml) for 24 h. Cells without treatment of interleukin-10 were used as controls (negative control). CCK-8 assay was performed every day at each time points (day 1, day 2, day 3, and day 4). The experiment was performed in quintuplicate. Data were shown as mean ± standard deviation. *P < 0.05 b a of cancers. [11] [12] [13] [14] [15] [16] [17] [18] For example, IL-10 promotes resistance to apoptosis and metastatic potential in lung cancer cell lines. [15] Overexpression of IL-10 leads to frequent event of immune evasion in esophageal squamous cell carcinoma. [17] IL-10 facilitates the progression of cervical cancer. [18] However, IL-10 is also reported to inhibit tumor development, growth, and metastasis in melanoma, colon cancer, and fibrosarcoma. [12, 14] Increased production of IL-10 was reported in glioma. [37, 38] In glioma, IL-10 stimulates the tumor-associated macrophages to express B7-H1, thus suppressing the immune system. [39] On the other hand, under the influence of glioma, microglia release several classes of molecules, including IL-10, that promote glioma growth, progression, and inflammatory activation. [40] To clarify the function of IL-10 in human glioma progression, we detected the glioma cell growth and invasion after treatment with IL-10. Our results and previous reports all revealed that IL-10 treatment promoted the glioma cell growth and invasion.
Heterogeneity is a hallmark of cancer. [41, 42] Thus, the mechanisms of tumor cell growth, invasion, migration, and metastasis in various types of tumor may be different, and there are many factors to promote tumor progression in the same type of tumor. For example, long noncoding RNAs, circular RNAs, cytokines, and migrating myeloid cells are all associated with glioma progression. [19, 22, [43] [44] [45] [46] [47] KPNA2 is a member of karyopherin α family. It promotes tumor progression in many kinds of tumors, including glioma, breast cancer, cervical cancer, colorectal cancer, and esophageal squamous cell carcinoma. [26] [27] [28] [29] [31] [32] [33] KPNA2 is required for IL-1β-induced MMP-mediated metastasis in oral were seeded in Matrigel-coated Transwell chamber overnight. Then, cell invasion assay was performed (a). Invasion cells were counted from at least five random fields at × 100 (b). Data were presented as mean ± standard deviation of three independent experiments. *P < 0.05 b a cavity squamous cell carcinoma. [48] KPNA2 also enhanced the TNFα-induced expression of IL-6, MMP-1, and MMP-13 and increased the P65 phosphorylation in human synovial sarcoma cells. [49] Thus, whether KPNA2 mediates IL-10-induced glioma cell growth and invasion remains unclear. In this study, we found that KPNA2 was significantly upregulated in glioma cells after treatment with IL-10. Using shRNA, knockdown of KPNA2 significantly inhibited glioma cell growth and invasion, suggesting that IL-10 maybe promote glioma cell growth dependent on KPNA2. However, further experiments will be necessary to identify the interaction of IL-10 with KPNA2.
In view of a recent study showing that KPNA2 plays a crucial role in the metabolic reprogramming of glioma cells by mediating the nuclear transportation of c-Myc and E2F1, [30] we hypothesize that IL-10 may have an important role in regulating the metabolism of glioma cells, but further experiments are needed to prove it.
CONCLUSIONS
We confirmed that IL-10 promoted glioma cell growth and invasion, and we proposed for the first time that IL-10 promoted glioma cell growth and invasion via upregulation of KPNA2. The present study provided a potential target for treatment of patients with glioma. 
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